GlassScriptPhysician profile
Francis M Gumbel
NPI 1912975251
$2,997.55
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $518 · 2021: $251 · 2022: $697 · 2023: $393 · 2024: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $409.40 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $365.93 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $286.41 | 2019-2021 | |
| Abbott Laboratories | $239.57 | 2019-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $211.04 | 2019-2023 | |
| Pfizer INC. | $205.48 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $149.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $117.06 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Dexcom, INC. | $97.49 | 2021-2022 | |
| Mylan Specialty L.P. | $96.19 | 2022 | |
| Amgen INC. | $94.16 | 2021-2024 | Evenity, Prolia |
| Intercept Pharmaceuticals, INC. | $81.53 | 2022 | |
| Exact Sciences Corporation | $75.79 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $73.45 | 2020-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $66.20 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.64 | 2019-2020 | |
| Mannkind Corporation | $45.25 | 2023-2024 | Afrezza |
| Radius Health, INC. | $42.67 | 2020-2023 | Tymlos |
| Astellas Pharma US INC | $41.34 | 2020-2024 | Veozah |
| Abbvie INC. | $41.08 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.34 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2022 | |
| Genentech USA, INC. | $23.41 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.52 | 2024 | Voquezna |
| Baxter Healthcare | $20.18 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Boston Scientific Corporation | $19.74 | 2023 | Watchman Flx |
| Allergan, INC. | $15.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.44 | 2022 | |
| Ascend Therapeutics US, LLC | $14.39 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Gumbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.